Company Overview and News


Add IIL
to your dashboard

Headline News

Innate's multiple sclerosis trials prove unsuccessful, new direction sought

2017-10-20 proactiveinvestors.com.au
Innate Immunotherapeutics Ltd (ASX:IIL) has outlined the company's Phase 2B trial of drug candidate MIS416 in patients with secondary progressive multiple sclerosis (SPMS) had been unsuccessful.

House Ethics Office Says New York Congressman May Have Violated Rules - The New York Times

2017-10-13 nytimes
Representative Chris Collins of New York may have violated federal law by sharing nonpublic information about a company on whose board he served, according to a report released Thursday by the Office of Congressional Ethics.

Trump’s Health Secretary Price Resigns Amid Private Jet Scandal - Bloomberg

2017-09-29 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Innate Immunotherapeutics reviews additional trial data, same result

2017-07-20 proactiveinvestors.com.au
Innate Immunotherapeutics Ltd (ASX:IIL) has further analysed its Phase 2B trial data on subjects with secondary progressive multiple sclerosis (SPMS), and the original findings have not changed.

Innate Immunotherapeutics up 39% backed by strong traded volumes

2017-07-11 proactiveinvestors.com.au
The rise was coupled with a marked spike in traded volumes in a stock that has been crushed of late following a negative result from the phase IIb clinical trials of its multiple sclerosis drug.

Innate Immunotherapeutics up 39% backed by strongly traded volumes

2017-07-11 proactiveinvestors.com.au
The rise was coupled with a marked spike in traded volumes in a stock that has been crushed of late following a negative result from the phase IIb clinical trials of its multiple sclerosis drug.

Republican congressmen are investing in health care stock for some reason

2017-07-07 deathandtaxesmag
As the GOP pushes forward in its attempt to repeal and replace Obamacare, Representative Mike Conaway and Senator James Inhofe are making sure they don’t miss out on the financial opportunity. Both Republican congressmen recently purchased tens of thousands of dollars worth of stock in UnitedHealth, one of the private insurance providers that stands to benefit from Washington wiping out regulations that help poor and sick individuals afford coverage.

How a key Donald Trump backer lost $22m overnight on an Australian drug company

2017-07-01 theage.com.au
US congressman Chris Collins has backed two horses in the past 18 months: Donald Trump, and an obscure Australian biotech firm called Innate Immunotherapeutics. Trump turned out to be a winner – Innate has been just the opposite.

How a key Donald Trump backer lost $22m overnight on an Australian drug company

2017-07-01 smh.com.au
US congressman Chris Collins has backed two horses in the past 18 months: Donald Trump, and an obscure Australian biotech firm called Innate Immunotherapeutics. Trump turned out to be a winner – Innate has been just the opposite.

Innate Immunotherapeutics is a leading ASX % Gainer in morning trade

2017-06-29 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

Cautionary Tale On 'Hot' Stocks And Confident Bets

2017-06-28 seekingalpha
Innate Immunotherapeutics (OTCPK:INNMF) is a small Australian biotech company whose main drug is an investigational treatment for multiple sclerosis. New York House Rep Chris Collins is a board member and was Innate's largest shareholder with a position valued at over $45 million earlier this year. Collins was very vocal in recommending the stock to friends, family and colleagues and bragging of how many millionaires he'd made by promoting the company:

Chris Collins-backed Innate Immunotherapeutics stock price drops 90% - Business Insider

2017-06-27 businessinsider
For years, Rep. Chris Collins has been an evangelist for Innate Immunotherapeutics, talking up the small Australian biotech company and enticing friends and congressional colleagues to buy its shares.

Innate Immunotherapeutics is the ASX Volume Leader in afternoon trade

2017-06-27 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

Innate Immunotherapeutics’ new drug application gets cleared by FDA

2017-06-21 proactiveinvestors.com.au
Innate Immunotherapeutics (ASX:IIL) has received clearance from the U.S. FDA for the Investigational New Drug (IND) application lodged last month for its lead drug candidate, MIS416.

Republican ‘spruiked Aussie share tip’

2017-06-08 perthnow.com.au
A REPUBLICAN Congressman allegedly spruiked an Australian pharmaceutical company to colleagues, reportedly telling them to buy shares.